Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure–activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

Add time:07/17/2019    Source:sciencedirect.com

(−)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin-5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.

We also recommend Trading Suppliers and Manufacturers of 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (cas 859213-39-1). Pls Click Website Link as below: cas 859213-39-1 suppliers

Prev:Inactivation of α-chymotrypsin by a bifunctional reagent, 2-bromomethyl-3,1-benzoxazin-4-one
Next:Visible-light-driven MIL-53(Fe)/BiOCl composite assisted by persulfate: Photocatalytic performance and mechanism)